{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:46:55Z","timestamp":1754146015582,"version":"3.41.2"},"reference-count":21,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7,1]]},"abstract":"<jats:p>Background: Dalfampridine extended release (D-ER) is indicated to improve walking in people with multiple sclerosis (MS) as demonstrated by an increase in walking speed. This study assessed the effects of D-ER on accelerometer-based measures in people with MS, including intensity of walking and total amount of walking during daily activities.<\/jats:p>\n               <jats:p>Methods: In this double-blind placebo-controlled crossover study, people with MS-related walking difficulty were randomized (1:1) to receive 4 weeks of D-ER 10 mg twice daily and 4 weeks of placebo in either order separated by a 2-week washout. Participants wore accelerometers for 7 days at baseline and week 3 of each on-drug period. The primary outcome was the peak activity index (PAI), defined as the most intense 30 individual minutes of the day (strides per minute). Secondary outcomes included daily step count, 6-Minute Walk Test (6MWT), Timed Up and Go (TUG) test, and patient-reported outcomes. A mixed-effects repeated-measures statistical model was used.<\/jats:p>\n               <jats:p>Results: Forty-three participants were randomized (mean Expanded Disability Status Scale score, 5.17). Least squares mean (standard error) change from baseline on the PAI was 0.6 (0.54) strides\/min on D-ER and 0.3 (0.55) strides\/min on placebo and in daily step count was 148.7 (222.4) on D-ER and 128.0 (225.4) on placebo. Other accelerometer-based measures and the 6MWT showed no significant differences between D-ER and placebo. The TUG test (P = .042) favored D-ER. There were no serious adverse events.<\/jats:p>\n               <jats:p>Conclusions: Dalfampridine did not show an effect on accelerometer-measured ambulatory activity in people with MS-related walking difficulty. More work is needed to confirm these results.<\/jats:p>","DOI":"10.7224\/1537-2073.2015-035","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T18:10:01Z","timestamp":1447870201000},"page":"170-176","source":"Crossref","is-referenced-by-count":8,"title":["A Randomized Crossover Trial of Dalfampridine Extended Release for Effect on Ambulatory Activity in People with Multiple Sclerosis"],"prefix":"10.7224","volume":"18","author":[{"given":"Theodore R.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia I.","family":"Simnad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4242","reference":[{"key":"2020060301085209300_i1537-2073-18-4-170-b1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0003-9993(86)90060-2","article-title":"Disability, disease duration, and rehabilitation service needs in multiple sclerosis: patient perspectives","volume":"67","author":"Kraft","year":"1986","journal-title":"Arch Phys Med Rehabil"},{"key":"2020060301085209300_i1537-2073-18-4-170-b2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"The natural history of multiple sclerosis: a geographically based study, I: clinical course and disability","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"key":"2020060301085209300_i1537-2073-18-4-170-b3","unstructured":"Schapiro\n              RT.\n            \n          \n          Multiple Sclerosis: A Rehabilitation Approach to Management. New York, NY: Demos; 1991."},{"key":"2020060301085209300_i1537-2073-18-4-170-b4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2165\/11591150-000000000-00000","article-title":"Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners","volume":"4","author":"La Rocca","year":"2011","journal-title":"The Patient"},{"key":"2020060301085209300_i1537-2073-18-4-170-b5","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","article-title":"Sustained release of oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial","volume":"373","author":"Goodman","year":"2009","journal-title":"Lancet"},{"key":"2020060301085209300_i1537-2073-18-4-170-b6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A phase 3 trial of extended release oral dalfampridine in multiple sclerosis","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann Neurol"},{"key":"2020060301085209300_i1537-2073-18-4-170-b7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jns.2009.12.021","article-title":"Accelerometry in persons with multiple sclerosis: measurement of physical activity or walking mobility?","volume":"290","author":"Weikert","year":"2010","journal-title":"J Neurol Sci"},{"key":"2020060301085209300_i1537-2073-18-4-170-b8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1682\/JRRD.2007.11.0197","article-title":"How humans walk: bout duration, steps per bout and rest duration","volume":"45","author":"Orendurff","year":"2008","journal-title":"J Rehabil Res Dev"},{"key":"2020060301085209300_i1537-2073-18-4-170-b9","article-title":"Sample grant text for StepWatch-related research. Orthocare Innovations website"},{"key":"2020060301085209300_i1537-2073-18-4-170-b10","first-page":"81","article-title":"Clinical predictors of falls and ambulatory activity in MS: 6-month prospective study [abstract]","volume":"9","author":"Wundes","year":"2007","journal-title":"Int J MS Care"},{"issue":"suppl","key":"2020060301085209300_i1537-2073-18-4-170-b11","first-page":"S47","article-title":"Predictors of community-based ambulatory activity: a prospective six month study of multiple sclerosis patients [abstract]","volume":"15","author":"Wundes","year":"2009","journal-title":"Mult Scler"},{"key":"2020060301085209300_i1537-2073-18-4-170-b12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0269215508101750","article-title":"The Physical Activity and Disability Survey\u2013Revised (PADS-R): an evaluation of a measure of physical activity in people with chronic neurological conditions","volume":"23","author":"Kayes","year":"2009","journal-title":"Clin Rehabil"},{"key":"2020060301085209300_i1537-2073-18-4-170-b13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.60.1.31","article-title":"Measuring the impact of MS on walking ability: the 12-item MS Walking Scale (MSWS-12)","volume":"60","author":"Hobart","year":"2003","journal-title":"Neurology"},{"key":"2020060301085209300_i1537-2073-18-4-170-b14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1682\/JRRD.2011.03.0063","article-title":"Accelerometer output and its association with energy expenditure in persons with multiple sclerosis","volume":"49","author":"Sandroff","year":"2012","journal-title":"J Rehabil Res Dev"},{"key":"2020060301085209300_i1537-2073-18-4-170-b15","doi-asserted-by":"crossref","first-page":"e93511","DOI":"10.1371\/journal.pone.0093511","article-title":"Accuracy of StepWatch\u2122 and ActiGraph accelerometers for measuring steps taken among persons with multiple sclerosis","volume":"9","author":"Sandroff","year":"2014","journal-title":"PLoS One"},{"issue":"suppl","key":"2020060301085209300_i1537-2073-18-4-170-b16","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1097\/00002060-200211001-00012","article-title":"Physical activity, health impairments, and disability in neuromuscular disease","volume":"81","author":"McDonald","year":"2002","journal-title":"Am J Phys Med Rehabil"},{"key":"2020060301085209300_i1537-2073-18-4-170-b17","first-page":"1450","article-title":"Quantification of walking mobility in multiple sclerosis (MS) using an ambulatory activity monitor","volume":"74","author":"Pearson","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2020060301085209300_i1537-2073-18-4-170-b18","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1136\/jnnp.2003.020180","article-title":"Activity indices for measuring mobility in neurologically impaired patients","volume":"75","author":"Busse","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2020060301085209300_i1537-2073-18-4-170-b19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1519\/JPT.0b013e31820aa921","article-title":"Validity of the StepWatch activity monitor: preliminary findings for use in persons with Parkinson disease and multiple sclerosis","volume":"34","author":"Schmidt","year":"2011","journal-title":"J Geriatr Phys Ther"},{"issue":"suppl 1","key":"2020060301085209300_i1537-2073-18-4-170-b20","first-page":"463","article-title":"Prolonged-release fampridine enhances physical activity during everyday life in patients with multiple sclerosis (FAMPKIN) [ACTRIMS\/ECTRIMS abstract P906]","volume":"20","author":"Weller","year":"2014","journal-title":"Mult Scler J"},{"key":"2020060301085209300_i1537-2073-18-4-170-b21","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1177\/0269215507075516","article-title":"The Physical Activity and Disability Survey (PADS): reliability, validity and acceptability in people with multiple sclerosis","volume":"21","author":"Kayes","year":"2007","journal-title":"Clin Rehabil"}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/18\/4\/170\/2091172\/1537-2073_2015-035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/18\/4\/170\/2091172\/1537-2073_2015-035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:12:39Z","timestamp":1752786759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/a-randomized-crossover-trial-of-dalfampridine-extended-release-for-effect-on-ambulatory-activity-in-people-with-multiple-sclerosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,1]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2015-035","relation":{},"ISSN":["1537-2073"],"issn-type":[{"type":"print","value":"1537-2073"}],"subject":[],"published":{"date-parts":[[2016,7,1]]}}}